Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to study enrollment\r\n* Myelosuppressive chemotherapy: patients must have completely recovered from all acute toxic effects of chemotherapy, immunotherapy or radiotherapy prior to study enrollment; at least  days must have elapsed since the completion of cytotoxic therapy, with the exception of hydroxyurea\r\n** Note: cytoreduction with hydroxyurea can be initiated and continued for up to  hours prior to the start of protocol therapy\r\n* Hematopoietic growth factors: at least  days after the last dose of a long-acting growth factor (e.g., pegfilgrastim) or  days for short-acting growth factor; for agents that have known adverse events occurring beyond  days after administration, this period must be extended beyond the time during which adverse events are known to occur\r\n* Biologic (anti-neoplastic agent): at least  days must have elapsed since completion of therapy with a biologic agent; for agents that have known adverse events occurring beyond  days after administration, this period prior to enrollment must be extended beyond the time during which adverse events are known to occur\r\n* Monoclonal antibodies:\r\n** At least  days after the completion of any type of immunotherapy, e.g. tumor vaccines \r\n** At least  half-lives must have elapsed since prior therapy that included a monoclonal antibody\r\n* Radiotherapy:\r\n** >=  weeks must have elapsed since local palliative external radiation therapy (XRT) (small port)\r\n** >=  months must have elapsed if prior craniospinal XRT was received, if >= % of the pelvis was irradiated, or if traumatic brain injury (TBI) was received\r\n** >=  weeks must have elapsed if other substantial bone marrow irradiation was given\r\n* Stem cell transplant or rescue without TBI: no evidence of active graft versus (vs.) host disease and >=  months must have elapsed since transplant
At least  days must have elapsed since the completion of therapy with a growth factor; at least  days must have elapsed after receiving pegfilgrastim
Prior anti-cancer therapy: at least  days must have elapsed between any prior anti-cancer therapy and first dose of AMG  Exceptions: Subjects who received conventional chemotherapy are eligible if at least  days have elapsed and if all treatment-related toxicity has been resolved to Grade . Prior palliative radiotherapy must have been completed at least  days before the first dose of AMG 
At least  days must have elapsed since the completion of therapy with a growth factor that supports platelet or white cell number or function. At least  days must have elapsed after receiving peg-filgrastim.
Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy\r\n* Patients must not have received myelosuppressive chemotherapy within  weeks of enrollment\r\n* Patients must be >  days since treatment with hematopoetic growth factors (>  days for Neulasta)\r\n* Patients must be >  days since therapy with a biologic agent and beyond the period for which adverse events of the biologic agent are known to occur if longer\r\n* Patients must be >  half-lives since therapy with a monoclonal antibody\r\n* Patients must be >  days since completion of any immunotherapy (i.e. tumor vaccines)\r\n* Patients must be greater than  weeks since most recent palliative XRT and greater than  weeks since substantial bone marrow irradiation\r\n* Patients must be greater than  weeks since prior stem cell transplant or infusion and without evidence of active graft versus (vs.) host disease
At least  days must have elapsed since the completion of cytotoxic therapy, with the exception of standard maintenance therapy and steroids
Patients may have received prior therapy including vincristine, irinotecan, or temozolomide; patients may not have previously been treated with combination therapy of irinotecan and temozolomide\r\n* Patients must be fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study\r\n** Patients must not have received myelosuppressive chemotherapy within  weeks of starting protocol therapy, or a minimum of six weeks must have elapsed since prior nitrosourea chemotherapy\r\n** At least  days must have elapsed since the last administration of filgrastim, or  days since administration of pegfilgrastim\r\n** At least  must have elapsed since the last administration of any biologic agent\r\n** At least  days since the last dose of local palliative radiation therapy; greater than  months must have elapsed since the last day of treatment if given total body irradiation, craniospinal irradiation\r\n** Complete resolution of graft versus host disease and no current need for immunosuppressive medication; greater than  months must have elapsed since engraftment and no longer requiring transfusion of platelets or injection of colony stimulating factors
Prior therapies\r\n* Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy\r\n* Myelosuppressive chemotherapy: Must not have received within  weeks ( weeks if prior nitrosourea)\r\n* Hematopoietic growth factors: At least  days since the completion of therapy with a growth factor,  days for long- acting (e.g. PEG-filgrastim)\r\n* Biologic (anti-neoplastic agent): At least  days or  half-lives (whichever is longer) since the completion of therapy with a biologic agent\r\n* Radiation therapy: >=  weeks must have elapsed from craniospinal radiation; >=  weeks must have elapsed from focal radiation\r\n* Surgery: >  weeks from major surgery; if recent craniotomy, adequate wound healing must be determined by neurosurgical team\r\n* Autologous stem cell transplant or rescue: No evidence of active graft versus (vs.) host disease and >=  weeks must have elapsed
Patients who relapse on therapy other than standard ALL maintenance therapy must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study\r\n* Cytotoxic chemotherapy: At least  days must have elapsed since the completion of cytotoxic therapy (other than standard ALL maintenance therapy) with the exception of hydroxyurea, which is permitted up to  hours prior to the start of protocol therapy\r\n* Nitrosoureas: At least  days must have elapsed since administration of nitrosoureas\r\n* Hematopoietic growth factors: At least  days after the last dose of long acting hematopoietic growth factor (e.g. Neulasta) or  days for short acting growth factor (e.g. Neupogen)\r\n* Radiation: At least  days must have elapsed since administration of craniospinal, hemipelvic or other radiation therapy to more than % of the bone marrow containing spaces; at least  days must have elapsed if other substantial marrow radiation has been given\r\n* Nelarabine prior therapy: Patients who have previously been treated with nelarabine are eligible, however if they have previously received a regimen of nelarabine, cyclophosphamide and etoposide, they are not eligible\r\n* Biologic (anti-neoplastic agent): At least  days after the last dose of a biologic agent; for agents that have known adverse events occurring beyond  days after administration, this period must be extended beyond the time during which adverse events are known to occur; the duration of this interval must be discussed with the study chair\r\n* Immunotherapy: At least  days after the completion of any type of immunotherapy (e.g. tumor vaccines or chimeric antigen receptor T cell (CART) therapy\r\n* Monoclonal antibodies: Monoclonal antibodies: At least  half-lives of the antibody must have elapsed after the last dose of a monoclonal antibody\r\n* Stem cell infusion: No evidence of active graft versus (vs.) host disease and at least  days must have elapsed after transplant or stem cell infusion\r\n* Study specific limitations on prior therapy: Patient may not have previously received therapy with an mTOR inhibitor\r\n* Prior intrathecal therapy: Patients may be enrolled on study regardless of the timing of prior intrathecal therapy; however, they MAY NOT BEGIN TREATMENT ON THIS PROTOCOL UNTIL A MINIMUM OF  DAYS HAS ELAPSED SINCE PRIOR INTRATHECAL THERAPY
Has recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy\r\n* Myelosuppressive chemotherapy: At least  weeks since completion ( weeks for nitrosourea)\r\n* Biologic (anti-neoplastic agent): At least  days since completion of therapy with a biologic agent\r\n* Radiation (XRT): ?  week must have elapsed from prior palliative XRT to non-target lesions
Prior therapy: there is no limit to the number of prior therapies provided all eligibility criteria are met; however, patients must have recovered from the acute toxic effects of all prior treatment\r\n* Patients must not have received prior therapy with either gemcitabine or nab-paclitaxel\r\n* Myelosuppressive chemotherapy: patients must not have received myelosuppressive chemotherapy within  weeks of protocol therapy on this study\r\n* Hematopoietic growth factors:  days must have elapsed from the start of protocol therapy since the completion of therapy with filgrastim, and  days must have elapsed from the start of protocol therapy after receiving pegfilgrastim\r\n* Biologic (anti-neoplastic agent):  days must have elapsed from the start of protocol therapy since the completion of therapy with a biologic agent\r\n* Monoclonal antibodies:  half-lives must have elapsed from the start of protocol therapy since prior therapy that included a monoclonal antibody\r\n* Radiotherapy:  weeks must have elapsed from the start of protocol therapy since local palliative radiation therapy (XRT) (small port);  months must have elapsed if % radiation of pelvis;  weeks must have elapsed if other substantial bone marrow irradiation was given\r\n* Stem cell transplant or rescue: no evidence of active graft versus (vs.) host disease and  months must have elapsed from the start of protocol therapy since transplant
PART  GROUP  INCLUSION CRITERIA:  A sufficient interval must have elapsed between the last dose of prior anti-cancer therapy (including cytotoxic and biological therapies) and enrollment in this study, to allow recovery from the acute toxic effects of all prior anti-cancer therapy:\r\n* Myelosuppressive chemotherapy: At least  days after the last dose of myelosuppressive chemotherapy\r\n* Hematopoietic growth factors: At least  days since the completion of therapy with a growth factor\r\n* Biologic (anti-neoplastic agent): At least  days after the last dose of a biologic agent\r\n* Immunotherapy: >=  days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =< ; at least  days after therapy with a cellular immunotherapy or anti-cancer vaccine\r\n* Radiation therapy: At least  days after local palliative radiation therapy (XRT) (small port); >=  weeks must have elapsed since treatment with therapeutic doses of metaiodobenzylguanidine (MIBG); >=  months must have elapsed from total body irradiation (TBI), craniospinal XRT or % radiation of pelvis\r\n* Stem Cell Transplant (SCT): At least  weeks after myeloablative therapy with autologous stem cell transplant (timed from start of protocol therapy); subjects must meet adequate bone marrow function definition (see organ function requirements, below) post-myeloablative therapy; patients who received stem cell reinfusion following non-myeloablative therapy are eligible once they meet peripheral blood count criteria below\r\n* Subjects with prior treatment with compound/s with the same mode of action used in one of the treatment groups are eligible if they have not previously received prior treatment with BOTH agents in the combination
PART  GROUP A INCLUSION CRITERIA: A sufficient interval must have elapsed between the last dose of prior anti-cancer therapy (including cytotoxic and biological therapies) and enrollment in this study, to allow recovery from the acute toxic effects of all prior anti-cancer therapy:\r\n* Myelosuppressive chemotherapy: At least  days after the last dose of myelosuppressive chemotherapy\r\n* Hematopoietic growth factors: At least  days since the completion of therapy with a growth factor\r\n* Biologic (anti-neoplastic agent): At least  days after the last dose of a biologic agent\r\n* Immunotherapy: >=  days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =< ; at least  days after therapy with a cellular immunotherapy or anti-cancer vaccine\r\n* Radiation therapy: At least  days after local palliative XRT (small port); >=  weeks must have elapsed since treatment with therapeutic doses of MIBG; >=  months must have elapsed from TBI, craniospinal XRT or % radiation of pelvis\r\n* SCT: At least  weeks after myeloablative therapy with autologous stem cell transplant (timed from start of protocol therapy); subjects must meet adequate bone marrow function definition (see organ function requirements, below) post-myeloablative therapy; patients who received stem cell reinfusion following non-myeloablative therapy are eligible once they meet peripheral blood count criteria below\r\n* Subjects with prior treatment with compound/s with the same mode of action used in one of the treatment groups are eligible if they have not previously received prior treatment with BOTH agents in the combination
PART  GROUP  INCLUSION CRITERIA: A sufficient interval must have elapsed between the last dose of prior anti-cancer therapy (including cytotoxic and biological therapies) and enrollment in this study, to allow recovery from the acute toxic effects of all prior anti-cancer therapy:\r\n* Myelosuppressive chemotherapy: At least  days after the last dose of myelosuppressive chemotherapy\r\n* Hematopoietic growth factors: At least  days since the completion of therapy with a growth factor\r\n* Biologic (anti-neoplastic agent): At least  days after the last dose of a biologic agent\r\n* Immunotherapy: >=  days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =< ; at least  days after therapy with a cellular immunotherapy or anti-cancer vaccine\r\n* Radiation therapy: At least  days after local palliative XRT (small port); >=  weeks must have elapsed since treatment with therapeutic doses of metaiodobenzylguanidine (MIBG); >=  months must have elapsed from TBI, craniospinal XRT or % radiation of pelvis\r\n* SCT: At least  weeks after myeloablative therapy with autologous stem cell transplant (timed from start of protocol therapy); subjects must meet adequate bone marrow function definition (see organ function requirements, below) post-myeloablative therapy; patients who received stem cell reinfusion following non-myeloablative therapy are eligible once they meet peripheral blood count criteria below\r\n* Subjects with prior treatment with compound/s with the same mode of action used in one of the treatment groups are eligible if they have not previously received prior treatment with BOTH agents in the combination
Prior therapy\r\n* Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study\r\n* Myelosuppressive chemotherapy: Patients must not have received myelosuppressive chemotherapy within  weeks of enrollment onto this study ( weeks if prior nitrosourea)\r\n* Hematopoietic growth factors: At least  days must have elapsed after receiving pegfilgrastim and least  days must have elapsed since the completion of therapy with a non-pegylated growth factor\r\n* Biologic (anti-neoplastic agent): At least  days must have elapsed since completion of therapy with a biologic agent; for agents that have known adverse events occurring beyond  days after administration, this period prior to enrollment must be extended beyond the time during which adverse events are known to occur\r\n* Monoclonal antibodies: At least  half-lives must have elapsed since prior therapy that included a monoclonal antibody\r\n* Radiotherapy: >=  weeks must have elapsed since local palliative external beam radiation therapy (XRT) (small port); >=  weeks must have elapsed since treatment with therapeutic doses of metaiodobenzylguanidine (MIBG); >=  months must have elapsed if prior craniospinal XRT was received, if >= % of the pelvis was irradiated, or if traumatic brain injury (TBI) was received; >=  weeks must have elapsed if other substantial bone marrow irradiation was given\r\n* Stem cell transplant or rescue without TBI: No evidence of active graft versus (vs.) host disease and >=  months must have elapsed since transplant
At least  days must have elapsed after receiving pegfilgrastim and least  days must have elapsed since the completion of therapy with a non-pegylated growth factor
The subject must have recovered from the acute toxic effects of all prior therapy with the exception of alopecia. The following time must have elapsed from the last dose of the following medications to study enrollment:\r\n* Myelosuppressive chemotherapy:  days\r\n* Hematopoietic growth factors:  days ( days for Neulasta)\r\n* Biologic agent:  days\r\n* Monoclonal antibody:  half-lives \r\n* Immunotherapy (ie tumor vaccines):  days\r\n* Palliative small port radiation therapy (XRT):  days\r\n* Substantial bone marrow XRT:  weeks\r\n* Stem cell transplant or infusion without total body irradiation (TBI):  weeks\r\n* Total body irradiation (TBI):  weeks
Biologic agents- At least  days must have elapsed since the completion of therapy with a biologic agent such as a monoclonal antibody. Seven days must have elapsed since the last dose of retinoids
Patient has fully recovered from the acute toxic effects of chemotherapy, immunotherapy, or radiation therapy prior to entering this study:\r\n* Myelosuppressive chemotherapy: patient has not received myelosuppressive chemotherapy within  weeks of enrollment onto this study ( and  weeks if prior temozolomide and nitrosourea, respectively)\r\n* Hematopoietic growth factors: at least  days must have elapsed since the completion of therapy with a growth factor; at least  days must have elapsed after receiving pegfilgrastim\r\n* Biologic (anti-neoplastic agent): at least  days must have elapsed since completion of therapy with a biologic agent; for agents that have known adverse events occurring beyond  days after administration, this period prior to enrollment must be extended beyond the time during which adverse events are known to occur\r\n* Monoclonal antibodies: at least three half-lives must have elapsed since prior therapy that included a monoclonal antibody\r\n* Radiation therapy: at least  months must have elapsed since any previous irradiation; unless measurable disease progression occurs at a site separate from the irradiated area and the patient has recovered from toxicities associated with radiation therapy
Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study and meet all of the following criteria:\r\n* Myelosuppressive chemotherapy:  days must have elapsed since the completion of myelosuppressive therapy; individuals may have received any of the following medications within  days without a wash-out period:\r\n** Standard maintenance therapy (vincristine, mercaptopurine [MP], corticosteroids, low dose methotrexate)\r\n** Hydroxyurea\r\n** Intrathecal chemotherapy with methotrexate, hydrocortisone and/or cytarabine\r\n* Radiation therapy (XRT):\r\n** Total body irradiation (TBI) or craniospinal radiation therapy: must have been completed more than  days from study entry\r\n** Palliative XRT: XRT for chloromas does not require a washout period\r\n* Biologic (anti-neoplastic agent): at least  days after the last dose of a biologic agent; for agents that have known adverse events occurring beyond  days after administration, this period must be extended beyond the time during which adverse events are known to occur; the duration of this interval must be discussed with the study chair\r\n* Immunotherapy: at least  weeks after the completion of any type of immunotherapy, e.g. tumor vaccines and chimeric antigen receptor T-cells\r\n* Monoclonal antibodies: at least  half-lives of the antibody after the last dose of a monoclonal antibody
Patients receiving maintenance biologic therapy are eligible, provided their recurrence is documented more than  months from completion of primary cytotoxic chemotherapy (includes maintenance chemotherapy) and a minimum of  weeks has elapsed since their last infusion of biologic therapy at the start of protocol intervention, day 
At least  days must have elapsed since the completion of therapy with a biologic agent such as a monoclonal antibody; seven days must have elapsed since the last dose of retinoids
Patients must have fully recovered from the acute toxic effects of chemotherapy, immunotherapy, surgery, or radiotherapy prior to entering this study:\r\n* Myelosuppressive chemotherapy: patient has not received myelosuppressive chemotherapy within  weeks of enrollment onto this study ( weeks if prior nitrosourea)\r\n* Hematopoietic growth factors: at least  days must have elapsed since the completion of therapy with a growth factor; at least  days must have elapsed after receiving pegfilgrastim\r\n* Biologic (anti-neoplastic agent): at least  days must have elapsed since completion of therapy with a biologic agent; for agents that have known adverse events occurring beyond  days after administration, this period prior to enrollment must be extended beyond the time during which adverse events are known to occur\r\n* Monoclonal antibodies: at least  half-lives must have elapsed since prior therapy that included a monoclonal antibody\r\n* Radiotherapy: at least  weeks must have elapsed since any irradiation; at least  weeks must have elapsed since craniospinal radiation therapy (RT) or substantial bone marrow irradiation
At least  days should have elapsed since the completion of therapy with a biologic agent
Patients must have had no chemotherapy, biologic therapy, or radiation therapy for their malignancy for at least  days prior to treatment; patients may have received localized radiation therapy to non-target lesions provided that the radiotherapy is completed  days prior to commencing therapy, and the patient has recovered from any toxicity; at least  half-lives must have elapsed since monoclonal antibody treatment; at least six weeks must have elapsed between mitomycin C or nitrosourea treatment
Inclusion Criteria:\n\n        - Patients must be ?  and ? years of age.\n\n        Diagnosis:\n\n        - Patients with AML must have ? % blasts (by morphology) in the bone marrow\n\n          -  Patients may have CNS or other sites of extramedullary disease. No cranial irradiation\n             is allowed during the protocol therapy.\n\n          -  Patients with secondary AML are eligible\n\n          -  Patients with Down syndrome and DNA fragility syndromes (such as Fanconi anemia, Bloom\n             syndrome) are excluded.\n\n        Performance Level:\n\n        - Karnofsky >% for patients > years of age and Lansky > % for patients ?  years of\n        age (See Appendix II for Performance Scales)\n\n        Prior therapy\n\n        - Patients must have fully recovered from the acute toxic effects of all prior\n        chemotherapy, immunotherapy, or radiotherapy prior to entering this study.\n\n          . Phase \n\n             - Any patient with AML in st or greater relapse, OR\n\n             - Patients with AML failed to go into remission after first or greater relapse, OR\n\n             - Patients with AML failed to go into remission from original diagnosis after two or\n             more induction attempts.\n\n          . Cytoreduction with hydroxyurea - Hydroxyurea can be initiated and continued for up to\n              hours prior to the start of decitabine/vorinostat. It is recommended to use\n             hydroxyurea in patients with significant leukocytosis (WBC >,/L) to control blast\n             count before initiation of systemic protocol therapy.\n\n          . Patients who relapsed while they are receiving cytotoxic therapy\n\n             - At least  days must have elapsed since the completion of the cytotoxic\n             therapy,except Intrathecal chemotherapy.\n\n             Hematopoietic stem cell transplant (HSCT):\n\n             - Patients who have experienced their relapse after a HSCT are eligible, provided they\n             have no evidence of acute or chronic Graft-versus-Host Disease (GVHD).\n\n             Hematopoietic growth factors:\n\n             - It must have been at least  days since the completion of therapy with GCSF or other\n             growth factors at the time of enrollment. It must have been at least  days since the\n             completion of therapy with pegfilgrastim (Neulasta )\n\n             Biologic (anti-neoplastic agent):\n\n             -At least  days after the last dose of a biologic agent. For agents that have known\n             adverse events occurring beyond  days after administration, this period must be\n             extended beyond the time during which adverse events are known to occur. The duration\n             of this interval must be discussed with the study chair.\n\n             Monoclonal antibodies: At least  half-lives of the antibody must have elapsed after\n             the last dose of monoclonal antibody (i.e. Gemtuzumab =  days)\n\n             Immunotherapy: At least  days after the completion of any time of immunotherapy,\n             e.g. tumor vaccines or CAR T-cell therapy.\n\n             XRT: Cranio or craniospinal XRT is prohibited during protocol therapy. No washout\n             period is necessary for radiation given to non-CNS chloromas; > days must have\n             elapsed if prior TBI, cranio or craniospinal XRT.\n\n             Prior Demethylating and/or HDAC Inhibitor Therapy: Patients who have received prior\n             DNMTi (e.g. decitabine) and/or HDACi (e.g. vorinostat) therapy are eligible to\n             participate in this Phase  study. At least  days must have passed from prior DNMTi\n             or HDACi as a washout period.\n\n             Renal and hepatic function: Patients must have adequate renal and hepatic functions as\n             indicated by the following laboratory values:\n\n             A. Adequate renal function defined as: Patient must have a calculated creatinine\n             clearance or radioisotope GFR ? ml/min/.m OR a normal serum creatinine based on\n             age/gender.\n\n             B. Adequate Liver Function Defined as: Direct bilirubin < . x upper limit of normal\n             (ULN) for age or normal, AND alanine transaminase (ALT) <  x ULN for age. The hepatic\n             requirements are waived for patients with known or suspected liver involvement by\n             leukemia. This must be reviewed by and approved by the study chair or vice chair.\n\n             Adequate Cardiac Function Defined as: Shortening fraction of ? % by echocardiogram,\n             OR ejection fraction of ? % by radionuclide angiogram (MUGA).\n\n             Reproductive Function A. Female patients of childbearing potential must have a\n             negative urine or serum pregnancy test confirmed within  weeks prior to enrollment.\n\n             B. Female patients with infants must agree not to breastfeed their infants while on\n             this study.\n\n             C. Male and female patients of child-bearing potential must agree to use an effective\n             method of contraception approved by the investigator during the study and for a\n             minimum of  months after study treatment.\n\n             Exclusion Criteria:\n\n             -No NG or G-Tube administration of Vorinostat is allowed. Capsule must be swallowed\n             whole or given as oral suspension.\n\n             -They are currently receiving other investigational drugs.\n\n             -There is a plan to administer non-protocol chemotherapy, radiation therapy, or\n             immunotherapy during the study period.\n\n             -They have significant concurrent disease, illness, psychiatric disorder or social\n             issue that would compromise patient safety or compliance, interfere with consent,\n             study participation, follow up, or interpretation of study results.\n\n             -They have a known allergy to any of the drugs used in the study.\n\n             -Patients with Down syndrome are excluded.\n\n               -  Patients with DNA fragility syndromes are excluded (e.g. Fanconi Anemia, Bloom\n                  Syndrome)\n\n               -  They are receiving valproic acid (VPA) therapy.\n\n               -  Patients with Acute Promyelocytic Leukemia (APL, APML) are excluded\n\n               -  Patients with documented active and uncontrolled infection at the time of study\n                  entry are not eligible
Refractory/recurrent patients\r\n* Patients must have recovered from the acute treatment related toxicities (defined as < grade ) of all prior chemotherapy, immunotherapy, radiotherapy or any other treatment modality prior to entering this study\r\n* Myelosuppressive chemotherapy\r\n** Patients must have received their last dose of known myelosuppressive anticancer therapy at least  days prior to enrollment or at least  days if nitrosourea\r\n* Biological agent: \r\n** Patient must have recovered from any acute toxicity potentially related to the agent and received their last dose of the biologic agent >=  days prior to study enrollment\r\n** For agents that have known adverse events occurring beyond  days after administration, this period must be extended beyond the time during which adverse events are known to occur\r\n* Monoclonal antibody treatment and agents with known prolonged half-lives: at least three half-lives must have elapsed prior to enrollment; \r\n** Note: a list of the half-lives of commonly used monoclonal antibodies is available on the Pediatric Brain Tumor Consortium (PBTC) webpage under Generic Forms and Templates\r\n* Radiation \r\n** Patients must have had their last fraction of: \r\n*** Craniospinal irradiation (>  Gy) or total body irradiation or radiation to >= % of pelvis >  months prior to enrollment\r\n*** Focal irradiation >  weeks prior to enrollment\r\n*** Local palliative irradiation (small port) >=  weeks\r\n* Autologous stem cell transplant \r\n** Patient must be >=  months since autologous bone marrow/stem cell transplant prior to enrollment and have CD counts above /mm^
Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study\r\n* Myelosuppressive anti-cancer therapy: must not have been received within  weeks of study entry ( weeks if prior nitrosourea)\r\n* Biologic (anti-neoplastic agent): at least  days since the completion of therapy with a biologic agent\r\n* Radiation therapy (RT): >=  weeks for local palliative radiation therapy (RT) (small port); >=  weeks must have elapsed if prior craniospinal RT or if >= % radiation of pelvis; >=  weeks must have elapsed if other substantial bone marrow (BM) radiation\r\n* Surgery: >=  weeks from last major surgery, including pulmonary metastasectomy, with the exclusion of a central line placement and core needle or small open biopsies
Subjects under the age of  must have had prior therapy according to the best available therapy as determined by their primary brain tumor specialist (to include oncology, neurosurgery and/or radiation oncology) including systemic and/or cranial or spinal radiation or chemotherapy; subjects over the age of  may be enrolled as part of first-line treatment; those subjects who enroll as first-line treatment will not be restricted from traditional treatments in the future; at least  days must have elapsed since completion of cranial radiotherapy and  days since completion of chemotherapy; at least  days must have elapsed since completion of total spine radiotherapy
Patients must have fully recovered from the acute non-hematologic toxic effects of all prior anti-cancer therapy, defined as resolution of all such toxicities to =< grade  or lower per the inclusion/exclusion criteria prior to entering this study\r\n* Myelosuppressive chemotherapy:\r\n** No waiting period will be required for patients receiving standard \maintenance-like\ chemotherapy including oral mercaptopurine, weekly low-dose oral methotrexate, and intermittent vincristine; otherwise, at least  days must have elapsed since the completion of cytotoxic therapy, with the exceptions of hydroxyurea or corticosteroids used for cytoreduction\r\n** Intrathecal cytotoxic therapy: No waiting period is required for patients having received intrathecal cytarabine, methotrexate, and/or hydrocortisone; intrathecal chemotherapy given at the time of diagnostic lumbar puncture (LP) to evaluate for relapse prior to study enrollment is allowed\r\n* At least  days must have elapsed since the completion of therapy with a growth factor; at least  days must have elapsed after receiving pegfilgrastim\r\n* At least  days must have elapsed since completion of therapy with a biologic agent (including tyrosine kinase inhibitors); for agents that have known adverse events occurring beyond  days after administration, this period prior to enrollment must be extended beyond the time during which adverse events are known to occur\r\n* At least  half-lives must have elapsed since prior therapy that included a monoclonal antibody with the exception of blinatumomab; patients must have been off blinatumomab infusion for at least  days and all drug related toxicity must have resolved to grade  or lower as outlined in the inclusion/exclusion criteria \r\n* >=  weeks must have elapsed since local palliative radiation therapy (XRT) (small port); >=  months must have elapsed if prior cranial or craniospinal XRT was received, if >= % of the pelvis was irradiated, or if total-body irradiation (TBI) was received; >=  weeks must have elapsed if other substantial bone marrow irradiation was given\r\n* At least  days must have elapsed since stem cell transplant and at least  days from donor lymphocyte infusion; patient must have had no more than one previous HSCT and currently have no evidence of active graft versus (vs.) host disease (GVHD)\r\n* At least  days must have elapsed from the last chimeric antigen receptor (CAR)-T cell infusion
Patients must have had no chemotherapy, biologic therapy, or radiation therapy for their malignancy for at least  days prior to treatment; patients may have received localized radiation therapy to non-target lesions provided that the radiotherapy is completed  days prior to commencing therapy, and the patient has recovered from any toxicity; at least  half-lives must have elapsed since monoclonal antibody treatment; at least six weeks must have elapsed between mitomycin C or nitrosourea treatment
Patients must have received standard treatment appropriate for their tumor type\r\n* Myelosuppressive chemotherapy: patients with solid tumors must not have received myelosuppressive chemotherapy within  weeks of enrollment onto this study ( weeks if prior nitrosourea)\r\n* Hematopoietic growth factors: at least  days must have elapsed after receiving pegfilgrastim and least  days must have elapsed since the completion of therapy with a non-pegylated growth factor\r\n* Biologic (anti-neoplastic agent): at least  days must have elapsed since completion of therapy with a biologic agent; for agents that have known adverse events occurring beyond  days after administration, this period prior to enrollment must be extended beyond the time during which adverse events are known to occur\r\n* Monoclonal antibodies: at least  half-lives must have elapsed since prior therapy that included a monoclonal antibody\r\n* Radiotherapy: >=  weeks must have elapsed since local palliative external beam radiation therapy (XRT) (small port); >=  weeks must have elapsed since treatment with therapeutic doses of MIBG; >=  months must have elapsed if prior craniospinal XRT was received, if >= % of the pelvis was irradiated, or if total body irradiation (TBI) was received; >=  weeks must have elapsed if other substantial bone marrow irradiation was given\r\n* Stem cell transplant or rescue without TBI: no evidence of active graft vs. host disease and >=  months must have elapsed since transplant
Prior therapy:\r\n* The patients malignancy must have relapsed after or failed to respond to frontline curative therapy and/or there must not be any curative treatment options available at the time of study entry\r\n* There is no limit to the number of prior treatment regimens; however, patients must have fully recovered from the acute toxic effects of prior chemotherapy, immunotherapy, or radiotherapy prior to study enrollment; any grade  or  non-hematologic toxicity of any previous therapy must have resolved to grade  or less\r\n* Myelosuppressive chemotherapy: patients must not have received myelosuppressive chemotherapy within  weeks of enrollment ( weeks if prior nitrosourea)\r\n* Hematopoietic growth factors: at least  days must have elapsed since the completion of therapy with a growth factor; at least  days must have elapsed after receiving pegfilgrastim\r\n* At least  days must have elapsed since the completion of therapy with a biologic agent, targeted agent, tyrosine kinase inhibitor or a metronomic non-myelosuppressive regimen\r\n* Monoclonal antibodies: at least  weeks must have elapsed since prior therapy that included a monoclonal antibody\r\n* Radiotherapy:  weeks must have elapsed since external beam radiation therapy (XRT)
Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy:\r\n* Myelosuppressive chemotherapy:\r\n** Solid tumors: Patients with solid tumors must not have received chemotherapy within  weeks of enrollment onto this study ( weeks if prior nitrosourea)\r\n** Lymphoma: Patients with lymphoma who relapse during standard maintenance therapy are eligible at time of relapse; for patients with ALCL who relapse while they are receiving cytotoxic therapy, at least  days must have elapsed since the completion of cytotoxic therapy; Note: cytoreduction with hydroxyurea can be initiated and continued for up to  hours prior to the start of PF-
At least  days must have elapsed since completion of myelosuppressive therapy
At least  days must have elapsed since the completion of therapy with a non-myelosuppressive biologic agent or retinoid
Patients must have fully recovered from the acute effects of all prior therapy and must meet the following criteria:\r\n* At least  days must have elapsed since the completion of myelosuppressive therapy\r\n* At least  hours must have elapsed since the completion of low-dose chemotherapy, such as hydroxyurea or low-dose cytarabine (up to  mg/m^/day)\r\n* For patients who have received prior HSCT, there can be no evidence of graft-versus-host disease (GVHD) and greater than  days must have elapsed since the HSCT; patients cannot be receiving therapy, including steroids, for the treatment or prevention of GVHD; all such medications must be discontinued at least  hours prior to enrollment
Immunomodulatory therapy: greater than  days must have elapsed since last dose of an immune modulating agent, including vaccine therapy
No limit is placed on the number of prior therapies; prior treatment with irinotecan or eribulin is allowed, although patients must not have received co-administration of eribulin and irinotecan and must not have had disease progression while receiving either eribulin or irinotecan; patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study\r\n* Must not have received within three weeks of start date of this protocol chemotherapy; six weeks is required after administration of nitrosourea agents\r\n* At least  days since the completion of therapy with a growth factor or at least  days for a long-acting growth factor (e.g. pegfilgrastim)\r\n* At least  days or  half-lives since the completion of therapy with a biologic agent, whichever is longer; for agents that have known adverse events occurring beyond  days after administration, this period must be extended beyond the time during which adverse events are expected to occur; the duration of this interval must be discussed with the principal investigator (PI) of the study\r\n* At least  weeks since the completion of any type of immunotherapy (e.g. tumor vaccines)\r\n* At least  half-lives must have elapsed since prior therapy that included a monoclonal antibody\r\n* Radiotherapy: >=  weeks for local palliative radiotherapy (XRT) (small port); >=  months must have elapsed if prior total body irradiation (TBI), craniospinal XRT; >=  months must have elapsed if >= % radiation of pelvis; >=  weeks must have elapsed if therapeutic doses of metaiodobenzylguanidine (MIBG) or other substantial bone marrow (BM) irradiation was given\r\n* Allogeneic and autologous hematopoietic stem cell transplant (HSCT) will be allowed, if there is no evidence of active graft vs. host disease and >=  months must have elapsed since infusion; patients must not be on systemic immunosuppression
Patients must have recovered (to Common Toxicity Criteria [CTC] version [v.]. =< grade  unless indicated below) from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study, with the exception of alopecia, weight changes and grade I or II lymphopenia\r\n* Myelosuppressive chemotherapy: must not have received within  weeks of entry onto this study ( weeks if prior nitrosourea or mitomycin-C)\r\n* Biologic (anti-neoplastic agent): at least  days after the last dose of a biologic agent; for agents that have known adverse events occurring beyond  days after administration, this period must be extended beyond the time during which adverse events are known to occur\r\n* Immunotherapy: at least  days after the completion of any type of immunotherapy, e.g. tumor vaccines\r\n* Monoclonal antibodies: at least  half-lives of the antibody after the last dose of a monoclonal antibody\r\n* Radiation therapy (RT): patients must have had their last fraction of craniospinal RT >=  months prior to study entry and their last fraction of focal RT >=  weeks prior to study entry; if the lesion used for on-study criteria is in the radiation field, there must be evidence of tumor progression after radiation therapy was completed\r\n* Study specific limitations on prior therapy:\r\n** Patients who have received thalidomide are eligible if all acute thalidomide-related toxicity has resolved\r\n** Patients must not have received lenalidomide previously
 days must have elapsed since the completion of myelosuppressive therapy; individuals may have received any of the following medications within  days without a wash-out period:\r\n* Hydroxyurea\r\n* Intrathecal chemotherapy with methotrexate, hydrocortisone and/or cytarabine
Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study\r\n* Myelosuppressive chemotherapy: must not have received within  weeks of entry onto this study ( weeks if prior nitrosourea)\r\n* Biologic (anti-neoplastic agent): at least  days since the completion of therapy with a biologic agent\r\n* Radiation therapy (RT): >=  weeks for local palliative RT (small port); >=  months must have elapsed if prior craniospinal RT or if >= % radiation of pelvis; >=  weeks must have elapsed if other substantial bone marrow (BM) radiation\r\n* Monoclonal antibodies: must not have received any monoclonal based therapies within  weeks, and all other immunotherapy (tumor vaccine, cytokine, or growth factor given to control the cancer) within  weeks, prior to study enrollment
Patient has fully recovered from the acute effects of all prior therapy and must meet the following criteria\r\n* At least  days must have elapsed since the completion of myelosuppressive therapy\r\n* At least  hours must have elapsed since the completion of low-dose of low-dose or non-myelosuppressive therapy, such as hydroxyurea or low-dose cytarabine (up to  mg/m^/day)\r\n* At least  days must have elapsed since the use of investigational agents\r\n* For patients who have received prior HSCT, there can be no evidence of GVHD and greater than  days must have elapsed since the HSCT; patients cannot be receiving therapy, including steroids, for GVHD; all such medications must be discontinued at least  hours prior to enrollment
Has recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy\r\n* Myelosuppressive chemotherapy: At least  weeks since completion ( weeks for nitrosourea)\r\n* Biologic (anti-neoplastic agent): At least  days since completion of therapy with a biologic agent\r\n* Radiation (XRT): >=  week must have elapsed from prior palliative XRT to non-target lesions
Participant must have recovered from the acute side effects of all prior anti-cancer therapy, and:\r\n* At least  weeks have elapsed since prior systemic cytotoxic chemotherapy (except intrathecal chemotherapy, hydroxyurea, low-dose cytarabine, and/or low dose maintenance therapy such as vincristine, mercaptopurine, methotrexate or glucocorticoids), and\r\n* If the participant received a prior allogeneic HSCT, at least  days have elapsed and there is no evidence of clinically significant graft versus host disease requiring treatment and/or have > grade  persistent non-hematologic toxicity related to a transplant
 days must have elapsed since the completion of cytotoxic therapy
At least  days since the completion of therapy with a biologic agent
Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study\r\n* Myelosuppressive chemotherapy: must not have received within  weeks of entry onto this study ( weeks if prior nitrosourea)\r\n* Biologic (anti-neoplastic agent): at least  days since the completion of therapy with a biologic agent\r\n* Bisphosphonates: at least  weeks since the completion of therapy with a bisphosphonate\r\n* Monoclonal antibodies: at least  half-lives must have elapsed since prior therapy that included a monoclonal antibody\r\n* Radiation therapy (RT): >=  weeks (wks) for local palliative RT (small port); >=  months must have elapsed if prior craniospinal RT or if >= % radiation of pelvis; >=  weeks must have elapsed if other substantial bone marrow (BM) radiation
Prior therapy: patients must have fully recovered from the acute toxic effects of all prior therapy prior to enrolling on study\r\n* Myelosuppressive chemotherapy: must not have received myelosuppressive therapy within  weeks prior to study entry ( weeks if nitrosourea)\r\n* Biologic (anti-neoplastic agent): at least  days since the completion of therapy with biologic agent, including retinoic acid; participants receiving Intravenous Immunoglobulin (IVIG) are eligible; however, participant must not receive IVIG during the  days of antibody infusion\r\n* Radiation therapy: at least  weeks since prior local radiation therapy at the time of study entry\r\n* Growth factors: must not have received hematopoietic growth factors (filgrastim [G-CSF], sargramostim [GM-CSF]) for at least  week prior to study entry\r\n* Investigational agent: must not have received investigational agent within  days of study entry\r\n* Immune therapy: must not have received immunosuppressive (including glucocorticoids), immunostimulatory or any immunomodulatory treatment within  weeks of study entry; steroid\r\ncontaining inhalers, steroid replacement for adrenal insufficiency and steroid premedication for prevention of transfusion or imaging contrast-agent related allergic reaction will be permitted
Greater than  days from completion of cytotoxic and biologic therapy and less than  days from previous therapy.
Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study\r\n* Myelosuppressive chemotherapy: must not have received within  weeks of entry onto this study\r\n* Biologic (anti-neoplastic agent): at least  days since the completion of therapy with a biologic agent\r\n* Immunotherapies: at least  days must have elapsed since a prior therapy that included a monoclonal antibody or any other type of immunotherapy (e.g. chimeric antigen receptor [CAR] T cell therapy)\r\n* Radiation therapy (RT): >=  weeks for local palliative RT (small port); >=  months must have elapsed if prior craniospinal RT or if >= % radiation of the pelvis; >=  weeks must have elapsed if other substantial bone marrow (BM) radiation
